Description of the medicine: Reaferon (Reaferonum)
Recombinant a 2 -interferon produced by the bacterial strain of pseudomonad, in the genetic apparatus of which the human leukocyte a 2-interferon gene is also integrated. Identical to human leukocyte a 2 - interferon.
Reaferon is a porous powder or porous mass of white color. Soluble in water. Hygroscopic.
It has antiviral, immunomodulating and antitumor activity.
Reaferon is used for viral and tumor diseases.
The drug is effective for viral hepatitis. Assign to adults in the treatment of acute viral hepatitis B. The drug is most effective at the beginning of the icteric period until the 5th day of illness. With developed hepatic coma and cholestatic hepatitis, the drug is not very effective.
Reaferon is used for viral conjunctivitis, keratoconjunctivitis, keratitis, uveitis, as well as for hairy cell leukemia, chronic myelogenous leukemia, and kidney cancer. There is also evidence of the use of reaferon in the treatment of multiple sclerosis.
Reaferon is prescribed intramuscularly, subconjunctively and locally.
For intramuscular administration, the contents of 1 ampoule are dissolved immediately before use in 1 ml of an isotonic sodium chloride solution.
In acute hepatitis B, 1,000,000 IU of reaferon is administered 2 times a day for 5 to 6 days, then for 5 days, 1,000,000 IU are used once a day. If necessary, continue to introduce 1,000,000 IU 2 times a week for 2 weeks. The total dose of reaferon per course of treatment is 15,000,000 20,000,000 IU.
With hairy cell leukemia, 3,000,000 6,000,000 IU is administered daily for 2 months. Maintenance therapy - 3,000,000 units 2 times a week. For the course of treatment 420 000 000 - 600 000 0000 IU.
With kidney cancer (stage IV), reaferon is administered at 3,000,000 IU daily for 10 days. Courses (3 - 9 or more) are repeated with an interval of 3 weeks. The total amount of the drug is from 90,000,000 to 270,000,000 IU or more.
In multiple sclerosis, 1,000,000 IU is administered 3 times a day for pyramidal syndrome and 1 to 2 times a day for cerebellar syndrome. It is administered within 10 days, then the number of administrations is reduced: in the same dose 1 time per week for 5-6 months.
In ophthalmic practice, reaferon is used in the form of subconjunctival injections and topically, in the form of eye drops. For subconjunctival administration and instillation, the contents of 1 ampoule are dissolved in 5 ml of isotonic sodium chloride solution.
Subconjunctively administered with stromal keratitis and keratoiridocyclitis at 60,000 IU in 0.3 ml daily or every other day, depending on the severity of the process. The course of treatment is 15 to 25 injections, which are carried out under local anesthesia with a 0.5% solution of dicain. With conjunctivitis and superficial keratitis, 2 drops of a solution are instilled into the conjunctival sac of the affected eye, starting from 6 to 8 times a day, then 3-4 times a day. The course of treatment is about 2 weeks.
When using reaferon, chills, general malaise, fever, skin allergic reactions (rash, itching), leuko- and thrombocytopenia are possible.